Abstract CT163: KEYNOTE-412: Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma

作者
Lillian L. Siu,Lisa Francesca Licitra,Yun Gan Tao,Chia‐Jui Yen,Danny Rischin,John N. Waldron,Barbara Ann Burtness,Vincent Grégoire,Sanjiv S. Agarwala,Jeffrey Thomas Yorio,Jean‐Pierre Delord,Sercan Aksoy,Sadakatsu Ikeda,Ruey‐Long Hong,Joy Yang Ge,Holly M. Brown,Behzad Bidadi,Jean‐Pascal Machiels
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:78 (13_Supplement): CT163-CT163 被引量:4
标识
DOI:10.1158/1538-7445.am2018-ct163
摘要

Abstract Background: Chemoradiation (CRT) with cisplatin is the standard of care for patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) not treated by surgery. Preclinical data in murine cancer models show improved tumor growth control and survival when radiation therapy (RT) is combined with a PD-1 inhibitor. Pembrolizumab is effective for treatment of recurrent/metastatic HNSCC, and initial results from a phase 1b study suggest that pembrolizumab plus CRT is tolerable in patients with LA-HNSCC. KEYNOTE-412 (NCT03040999) is a phase 3, randomized, placebo-controlled, double-blind trial to determine the efficacy and safety of pembrolizumab given with CRT and as maintenance therapy versus placebo plus CRT in LA-HNSCC. Trial design: Patients will be randomly assigned (1:1) to receive pembrolizumab 200 mg every 3 weeks plus cisplatin-based CRT or placebo plus cisplatin-based CRT. Treatment will be stratified by RT regimen (accelerated RT [56-70 Gy, 6 fractions/week for 6 weeks] or standard RT [56-70 Gy, 5 fractions/week for 7 weeks]), tumor site/p16 status (oropharynx p16 positive vs p16 negative or larynx/hypopharynx/oral cavity), and disease stage (III vs IV). A priming dose of pembrolizumab or placebo will be given 1 week before CRT, followed by 2 doses during CRT and an additional 14 doses after CRT, for a total of 17 pembrolizumab or placebo infusions. Eligibility criteria include age ≥18 years; newly diagnosed, treatment-naive, oropharyngeal p16 positive (any T4 or N3), oropharyngeal p16 negative (any T3-T4 or N2a-N3), or larynx/hypopharynx/oral cavity (any T3-T4 or N2a-N3) SCC; evaluable tumor burden (RECIST v1.1); and ECOG performance status 0-1. Treatment will be discontinued at centrally confirmed disease progression, unacceptable toxicity, or patient/physician decision to withdraw. Response will be assessed by computed tomography or magnetic resonance imaging 12 weeks after CRT, every 3 months for 3 years, then every 6 months for years 4 and 5. Patients will be evaluated to determine the necessity of neck dissection 12 weeks after completion of CRT; neck dissection will be recommended in cases of persistent disease. After a patient experiences disease progression or starts new anticancer therapy, the patient will begin survival follow-up and will be contacted every 3 months during years 1 through 3 and every 6 months during years 4 and 5 until death, withdrawal of consent, or the end of the study, whichever occurs first. Safety will be monitored throughout the study and for 30 days after treatment end. The primary end point is event-free survival. Secondary end points include overall survival, safety, and patient-reported outcomes. Recruitment is ongoing in 21 countries and will continue until ~780 patients are enrolled. Citation Format: Lillian L. Siu, Lisa Licitra, Yun Gan Tao, Chia-Jui Yen, Danny Rischin, John Waldron, Barbara Burtness, Vincent Gregoire, Sanjiv Agarwala, Jeffrey Yorio, Jean-Pierre DeLord, Sercan Aksoy, Sadakatsu Ikeda, Ruey-Long Hong, Joy Yang Ge, Holly Brown, Behzad Bidadi, Jean-Pascal Machiels. KEYNOTE-412: Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr CT163.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
HappyR完成签到,获得积分10
1秒前
kokok完成签到,获得积分10
1秒前
小黑发布了新的文献求助10
1秒前
redamancy完成签到 ,获得积分10
1秒前
易128_完成签到,获得积分10
1秒前
h11的应助被T0Yu采纳,获得10
1秒前
1秒前
lry5211完成签到,获得积分10
1秒前
忧虑的汽车完成签到,获得积分10
2秒前
全能完成签到,获得积分10
2秒前
礼赞_完成签到,获得积分10
2秒前
2秒前
123完成签到,获得积分10
2秒前
cc完成签到,获得积分10
2秒前
2秒前
阳光的笑卉完成签到,获得积分10
3秒前
高分子聚合绿豆汤完成签到 ,获得积分10
3秒前
ll发布了新的文献求助40
3秒前
派大星完成签到,获得积分10
4秒前
4秒前
4秒前
天天开心完成签到,获得积分10
4秒前
缥缈芒果完成签到,获得积分10
6秒前
ZZD完成签到 ,获得积分10
6秒前
开心的老虎完成签到,获得积分10
6秒前
zjw发布了新的文献求助30
6秒前
灰灰完成签到,获得积分10
7秒前
kokok发布了新的文献求助20
7秒前
7秒前
敏感寒云完成签到,获得积分10
7秒前
JG发布了新的文献求助10
7秒前
ing完成签到 ,获得积分10
7秒前
青柳安发布了新的文献求助10
8秒前
ERIC完成签到,获得积分10
8秒前
Jenny完成签到,获得积分10
8秒前
溜溜完成签到,获得积分10
8秒前
wwww发布了新的文献求助10
8秒前
8秒前
8秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159633
求助须知:如何正确求助?哪些是违规求助? 9555145
关于积分的说明 21725138
捐赠科研通 7749593
什么是DOI,文献DOI怎么找? 3427281
关于科研通互助平台的介绍 2552345
邀请新用户注册赠送积分活动 2471619